Evotec to Voluntarily Delist From NASDAQ

HAMBURG, Germany, Nov. 10, 2009 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT)
(TecDAX), a leading provider in the discovery and development of novel small
molecule drugs today announced that it plans to voluntarily delist its American
Depositary Shares from the NASDAQ stock market and concentrate its share trading
on the recently re-entered TecDAX platform.

Dr. Werner Lanthaler, Chief Executive Officer of Evotec stated: "Evotec follows
the trading behaviour of its shareholders thereby reducing unnecessary
complexity in the capital market presence and related costs. Despite this
delisting we intend to continually improve the information and service quality
for our global shareholder base."

Evotec has given formal notice to the NASDAQ of its intention to voluntarily
delist its American Depositary Shares. Evotec intends to file a Form 25 with the
NASDAQ on 20 November 2009 to initiate the delisting which will become effective
on 30 November 2009. As soon thereafter as the Company is eligible, the Company
intends to file a Form 15 with the Securities and Exchange Commission to
terminate the registration of the American Depositary Shares and the underlying
ordinary shares.

During the second quarter of 2008 Evotec acquired Renovis and, in the context of
this transaction, listed on NASDAQ. The Evotec ADSs are listed on the NASDAQ
Global Market under the trading symbol "EVTC". Based on the "Evotec 2012 -
Action Plan to Focus and Grow" Evotec implemented strict restructuring measures
during the course of the second quarter 2009. As a consequence of these
measures, Evotec closed its U.S. operations in South San Francisco, California,
during the third quarter 2009.

About Evotec AG

Evotec is a leader in the discovery and development of novel small molecule
drugs. The Company has built substantial drug discovery expertise and an
industrialized platform that can drive new innovative small molecule compounds
into the clinic. In addition, Evotec has built a deep internal knowledge base in
the treatment of diseases related to neuroscience, pain, and inflammation.
Leveraging these skills and expertise the Company intends to develop
best-in-class differentiated therapeutics and deliver superior science-driven
discovery alliances with pharmaceutical and biotechnology companies. Evotec has
long-term discovery alliances with partners including Boehringer Ingelheim,
CHDI, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in
clinical development and a series of preclinical compounds and development
partnerships, including for example a strategic alliance with Roche for the EVT
100 compound family, subtype selective NMDA receptor antagonists for use in
treatment-resistant depression. For additional information please go to
www.evotec.com.

Forward-Looking Statements

Information set forth in this press release contains forward-looking statements,
which involve a number of risks and uncertainties. Such forward-looking
statements include, but are not limited to, statements about our expectations
and assumptions concerning regulatory, clinical and business strategies, the
progress of our clinical development programs and timing of the results of our
clinical trials, strategic collaborations and management's plans, objectives and
strategies. These statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. In particular, the risks and
uncertainties include, among other things: risks that the Company may be unable
to reduce its cash burn through recent restructuring and cost containment
measures and may not recognize the results of such measures within the expected
timeframe; risks that product candidates may fail in the clinic or may not be
successfully marketed or manufactured; the risk that we will not achieve the
anticipated benefits of our collaborations, partnerships and acquisitions in the
timeframes expected, or at all; risks relating to our ability to advance the
development of product candidates currently in the pipeline or in clinical
trials; our inability to further identify, develop and achieve commercial
success for new products and technologies; the risk that competing products may
be more successful; our inability to interest potential partners in our
technologies and products; our inability to achieve commercial success for our
products and technologies; our inability to protect our intellectual property
and the cost of enforcing or defending our intellectual property rights; our
failure to comply with regulations relating to our products and product
candidates, including FDA requirements; the risk that the FDA may interpret the
results of our studies differently than we have; the risk that clinical trials
may not result in marketable products; the risk that we may be unable to
successfully secure regulatory approval of and market our drug candidates; and
risks of new, changing and competitive technologies and regulations in the U.S.
and internationally.

The list of risks above is not exhaustive. Our most recent Annual Report on Form
20-F, filed with the Securities and Exchange Commission, and other documents
filed with, or furnished to the Securities and Exchange Commission, contain
additional factors that could impact our businesses and financial performance.
We expressly disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on which any
such statement is based.

-0-
CONTACT: Evotec AG
Dr. Werner Lanthaler, Chief Executive Officer
+49.(0)40.56081-242
werner.lanthaler@evotec.com